Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Cytomegalovirus (CMV) is one of the most important opportunistic infections in transplant recipients. Tests for CMV-specific T cell responses have been proposed to change the current risk stratification strategy using CMV assays. We evaluated the usefulness of pre-transplant CMV-specific T cell assays in kidney transplant (KT) candidates for predicting the development of CMV infection after transplantation comparing the results of the overlapping peptides (OLPs)-based enzyme-linked immunospot (ELISPOT) assay and the commercial QuantiFERON-CMV assay. We prospectively enrolled all cases of KT over a 5-month period, except donor CMV-seropositive and recipient seronegative transplants that are at highest risk of CMV infection. All the patients underwent QuantiFERON-CMV, CMV OLPs-based pp65, and immediate-early 1 (IE-1)-specific ELISPOT assays before transplantation. The primary outcome was the incidence of CMV infection at 6 months after transplant. The total of 47 KT recipients consisted of 45 living-donor KTs and 2 deceased-donor KTs. There was no association between positive QuantiFERON-CMV results and CMV infection. However, 10 of 34 patients with phosphoprotein 65 (pp65)- or IE-1-specific ELISPOT results higher than cut-off value developed CMV infections compared with none of 13 patients with results lower than cut-off value developed CMV. The OLPs-based ELISPOT assays are more useful than the QuantiFERON-CMV assay for predicting CMV infection. Patients with higher CMV-specific T cell immunity at baseline appear to be more likely to develop CMV infections after KT, suggesting that the abrupt decline in CMV-specific T cell responses after immunosuppression, or high CMV-specific T cell responses due to frequent CMV activation before KT, may promote CMV infection.
Abstract
Cytomegalovirus (CMV) is one of the most important opportunistic infections in transplant recipients. Tests for CMV-specific T cell responses have been proposed to change the current risk stratification strategy using CMV assays. We evaluated the usefulness of pre-transplant CMV-specific T cell assays in kidney transplant (KT) candidates for predicting the development of CMV infection after transplantation comparing the results of the overlapping peptides (OLPs)-based enzyme-linked immunospot (ELISPOT) assay and the commercial QuantiFERON-CMV assay. We prospectively enrolled all cases of KT over a 5-month period, except donor CMV-seropositive and recipient seronegative transplants that are at highest risk of CMV infection. All the patients underwent QuantiFERON-CMV, CMV OLPs-based pp65, and immediate-early 1 (IE-1)-specific ELISPOT assays before transplantation. The primary outcome was the incidence of CMV infection at 6 months after transplant. The total of 47 KT recipients consisted of 45 living-donor KTs and 2 deceased-donor KTs. There was no association between positive QuantiFERON-CMV results and CMV infection. However, 10 of 34 patients with phosphoprotein 65 (pp65)- or IE-1-specific ELISPOT results higher than cut-off value developed CMV infections compared with none of 13 patients with results lower than cut-off value developed CMV. The OLPs-based ELISPOT assays are more useful than the QuantiFERON-CMV assay for predicting CMV infection. Patients with higher CMV-specific T cell immunity at baseline appear to be more likely to develop CMV infections after KT, suggesting that the abrupt decline in CMV-specific T cell responses after immunosuppression, or high CMV-specific T cell responses due to frequent CMV activation before KT, may promote CMV infection.
참고문헌 (20)
- 김성한, "Diagnostic Usefulness of Cytomegalovirus (CMV)- Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of- Concept Study", Infection and Chemotherapy, 47(2), pp.105~110 (2015), 대한감염학회[DOI]
- Tark Kim, "Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy", The Korean Journal of Internal Medicine, 31(5), pp.961~970 (2016), 대한내과학회[DOI]
- Han JS, "A survey on the cytomegalovirus antibodies in blood donors and the diseased", Korean J Blood Transfus, 1, pp.21~34 (1990)
- Jung J, "Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients", J Clin Virol, 87, pp.5~11 (2017)
- Lochmanova A, "Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation", Transplant Proc, 42, pp.3574~3577 (2010)
- Cantisán S, "Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation", Am J Transplant, 13, pp.738~745 (2013)
- Rittà M, "Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients", New Microbiol, 38, pp.329~335 (2015)
- Forner G, "Cytomegalovirus (CMV) enzyme-linked immunosorbent spot assay but not CMV QuantiFERON assay is a novel biomarker to determine risk of congenital CMV infection in pregnant women", J Clin Microbiol, 54, pp.2149~2154 (2016)
- Saldan A, "Strong cell-mediated immune response to human cytomegalovirus is associated with increased risk of fetal infection in primarily infected pregnant women", Clin Infect Dis, 61, pp.1228~1234 (2015)
- Distler E, "Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation", Biol Blood Marrow Transplant, 14, pp.1417~1424 (2008)
- Schachtner T, "The loss of BKV-specific Immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication", Am J Transplant, 15, pp.2159~2169 (2015)
- Snyder LD, "Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation", Am J Respir Crit Care Med, 193, pp.78~85 (2016)
- Solano C, "Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation", J Clin Microbiol, 39, pp.3938~3941 (2001)
- Chiereghin A, "Monitoring cytomegalovirus T-cell immunity in small bowel", multivisceral transplant recipients, 2010, pp.42, 69~73
- Costa C, "Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients", Transplant Proc, 43, pp.1159~1161 (2011)
- Abate D, "Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection", J Clin Microbiol, 50, pp.1974~1980 (2012)
- Patel M, "Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients", Pediatr Transplant, 16, pp.18~28 (2012)
- Westall GP, "Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity", Am J Transplant, 8, pp.1749~1754 (2008)
- Lisboa LF, "Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia", Transplantation, 93, pp.195~200 (2012)
- Kim SH, "A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients", Am J Transplant, 11, pp.1927~1935 (2011)